pp-269 Tablets
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Cancer, Solid tumor, Leukemia, Lymphoma, Neuroblastoma, Gastrointestinal tumor, Genitourinary tract tumor, Head and neck tumor, Anorectal tumor, Colon tumor, Ovary tumor
Clinical stage: Phase 2
Modality: Small molecule inhibitor
Mechanism & Target: Cell cycle inhibitor, Anticancer protein kinase inhibitor, Mitotic G2 phase pathway modulator, Double strand break repair pathway modulator, Mitotic G2 M phase transition pathway modulator, DNA repair pathway modulator
Route & form: Oral
Differentiation: it is a highly selective, orally available, small molecule inhibitor of Checkpoint kinase 1 (Chk1).
Manufacturer #39681
A clinical-stage biopharmaceutical company focused on oncology. Developing a small molecule therapeutic targeting oncology with global development focus. Pipeline positioned for regulatory advancement in key markets.
None